Frontlight ResearchEarly access
WithdrawnPhase 2
A Trial of LY3056480 in Patients With SNLH
Key facts
- Who runs it
- Audion Therapeutics BV
- Where
- Chicago, New York, and Norfolk, United StatesSee the 3 sites
- Trial code
- Status
- Withdrawn
- Phase
- Phase 2
- Started
- Sept 2022
- Ended
- Mar 2025
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- LY3056480
- Record updated
- 25 August 2022
- Why it stopped
- Study put on hold
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 11 criteriaShow less
Who can take part
- Male or female between 18 - 65 years of age
- Minimum of six months of documented stable hearing loss (+/- 5dB)
- A documented stable word recognition test (stable for ~ 6 months +/- 6%/3 words)
Who cannot take part
- Any therapy known as ototoxic
- Participant in a previous trial of LY3056480
- History of suspected or diagnosed genetic cause of hearing loss
- Suspected or known diagnosis of the following inner ear pathology, congenital hearing loss, fluctuating hearing loss, Ménière's disease, or secondary endolymphatic hydrops, perilymph fistula, cochlear barotrauma, autoimmune hearing loss, radiation-induced hearing loss, retro-cochlear lesion, ototoxicity
- Evidence of acute or chronic otitis media or otitis externa on examination; or a history of middle ear pathology and/or surgery (except for ear tubes as a child)
- Presenting with a primary complaint of tinnitus
- Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10 dB at two or more contiguous octave frequencies in the study ear
- Partial deafness as defined as hearing loss in any frequency (up to 8 kHz) greater than 80dB
Where in United States
- Northwestern University Feinberg School of MedicineChicago, United States
- New York Eye and Ear Infirmary ICAHN school of Medicine Mount SinaiNew York, United States
- Eastern Virginia Medical SchoolNorfolk, United States
About the trial
What the trial wants to find out
A phase 2 trial with LY3056480 in patients with stable SNHL
The 2 groups in the trial
- Four injections of 250µg LY3056480Treatment being tested
The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below. * Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11 * Group 2 - Regimen 2. Weekly * Group 3 - Regimen 3. Every two weeks
Treatment: LY3056480
- Four injections of placeboPlacebo, for comparison
The treatment will be given transtympanically over the course of 2-7 weeks, according to dosing regimens below. * Group 1 - Regimen 1. Day 1, Day 4, Day 8, Day 11 * Group 2 - Regimen 2. Weekly * Group 3 - Regimen 3. Every two weeks
Treatment: LY3056480
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 2 Double Blind, Randomized, Placebo Controlled Trial inVEstigating the Effect and Safety of Several Dosing Regimens of LY3056480 in Patients With STAble Sensorineural Hearing Loss
- Record updated
- 25 August 2022